Blood pressure medication recall expands again to include losartan

FDA recalls another blood pressure medication over concerns of cancer-causing ingredients

56,000 bottles of blood pressure medication recalled

That's after trace amounts of a potential carcinogen were found to be in the medicine. Other companies to announce recalls include Maylan, Aurobindo Pharma and Torrent Pharmaceuticals, which also listed Hetero Labs as the source of the contamination in its recall.

Camber Pharmaceuticals is voluntarily recalling 87 lots of the blood pressure drug Losartan due to traces of a potential carcinogen.

Since last summer, drug companies have recalled hundreds of lots of blood pressure and heart medication drugs after tests showed small levels of potentially cancer-causing impurities.

AurobindoPharma USA announced its voluntary recall on Friday of 38 lots of medication that included tablets of valsartan and another in which valsartan is combined with amlodipine.

The remedy is packaged in 30 rely upon, 90 depend, 500 depend and 1000 rely on bottles.

Presently, Illinois-based compliance company Stericycle is working with Camber to notify distributors and customers of the recall.

The medication is used to treat high blood pressure and congestive heart failure. The affected Losartan tablets have expiration dates that range from September 2019 to June 2020.

WWE stars pay tribute to King Kong Bundy
WWE said in a release that it was saddened to learn of Bundy's death, expressing condolences to his family, friends and fans. WWE also acknowledged Bundy's passing, remembering his impact on the wrestling business in the 1980s.

A series of drugs have been identified as potentially unsafe since an initial recall began seven months ago.

Now, the FDA is "deeply concerned" about the presence of a third impurity in certain ARB medications, Commissioner Dr. Scott Gottlieb said in the news release.

"FDA scientists have developed novel and sophisticated testing methods specifically created to detect and measure N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) impurities in [angiotensin II receptor blocker (ARB)] medicines", Gottlieb wrote.

The FDA said in a statement it was investigating the formation of these impurities, which were reported to be made by previously unknown to drug developers.

The latest such cases on Friday had two pharmaceutical firms expanding previous recalls.

From a community pharmacy perspective, this recall has been hard because many pharmacies don't keep the lot numbers of medications after they're dispensed, Freeman said: "That information is not tracked effectively".

Latest News